1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Application deadline was May 22, 2026; today is May 26, 2026, so the deadline has passed.
Marty Robson Burn Wound Infection Research Grant is sponsored by Wound Healing Foundation (WHF), Urgo Medical North America, and American Burn Association (ABA). This grant supports innovative research in the prevention and treatment of burn wound infection, honoring the legacy of Martin C. Robson, MD.
Get alerted about grants like this
Save a search for “Wound Healing Foundation (WHF), Urgo Medical North America, and American Burn Association (ABA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Wound Healing Foundation and American Burn Association Open Call for Applications for Marty Robson Burn Wound Infection Research Grant Apply by June 15 for the ABA-BCEN Nursing Advancement Scholarship Wound Healing Foundation and American Burn Association Open Call for Applications for Marty Robson Burn Wound Infection Research Grant The Wound Healing Foundation (WHF), in partnership with Urgo Medical North America and the American Burn Association (ABA), is now accepting applications for the Marty Robson Burn Wound Infection Research Grant , a $15,000 award supporting innovative research in the prevention and treatment of burn wound infection.
The grant honors the legacy of Martin C. Robson, MD, and supports early-stage, high-impact research that advances understanding and care for burn wound infections. Funding is intended for direct research expenses and is awarded to emerging investigators conducting wound healing research.
“Burn wound infection remains one of the most complex challenges in acute burn care,” said ABA’s CEO, Ed Dellert, RN, MBA, CAE, FACEHP. “This grant reflects a shared commitment to advancing research that can directly inform prevention and treatment strategies, while supporting the next generation of investigators in the field.
” “Through the Marty Robson Burn Wound Infection Research Grant, the Wound Healing Foundation remains focused on accelerating innovative science in wound healing,” said Wound Healing Foundation's Vice Chair, Laura K. S. Parnell.
“Partnering with Urgo Medical North America and the American Burn Association strengthens the reach and impact of this work and helps ensure promising research ideas are given the opportunity to develop into meaningful clinical advances. ” The $15,000 grant supports one-year research projects focused on topical treatment or prevention of burn wound infection.
Applicants must meet eligibility criteria outlined by WHF, including early-career investigator status and institutional support requirements. Full application details and submission instructions are available on the Wound Healing Foundation website.
The mission of the Wound Healing Foundation, a 501(c)3 nonprofit organization, is to improve the quality of life of wound healing patients and their families, enabling more people to achieve optimal wound healing through awareness, education, and research.
WHF has demonstrated longstanding commitment and expertise in building awareness, creating and disseminating diverse educational resources grounded in clinical evidence, and supporting continued innovative research in wound care, thereby expanding access to quality wound care practices and supporting optimal healing for wound patients. For more information, visit woundhealingfoundation. org .
The American Burn Association (ABA) is dedicated to improving the lives of those affected by burn injuries through advocacy, education, research, and prevention. Founded in 1967, the ABA supports burn care professionals and organizations and works to advance the quality of burn care worldwide. For more information, visit ameriburn.
org . Urgo Medical North America is dedicated to advancing wound & burn care by ensuring that both patients and clinicians have access to the highest standard of solutions and support. The company focuses on delivering clinically effective products designed to improve healing outcomes while empowering healthcare professionals with practical, evidence-based tools.
For more information, visit urgomedical. us .
According to the current listing, eligibility includes: Emerging investigators conducting wound healing research who meet eligibility criteria outlined by WHF, including early-career investigator status and institutional support requirements. Confirm the full requirements in the official notice before applying.
The current listing shows $15,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was May 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Marty Robson Burn Wound Infection Research Grant is funded by Wound Healing Foundation (WHF), Urgo Medical North America, and American Burn Association (ABA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
DARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read articleOn June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleThe BARK program funds dual-use medical products for warfighters and military working dogs — tourniquets, sensors, drug delivery, and CBRN countermeasures. Proposals close June 3, 2026.
Read article